Fomivirsen: A Viewpoint by David W. Johnson

Johnson, D.W.
March 1999
Drugs;Mar1999, Vol. 57 Issue 3, p381
Academic Journal
Comments on the use of the drug fomivirsen in the treatment of cytomegalovirus retinitis in patients with AIDS. Mechanism of action of fomivirsen; Details on the dosage and adminsitration of fomivirsen; Information on possible complications related to the use of fomivirsen.


Related Articles

  • New CMV drug may have lower cost and risks. McCue, Mike // Ophthalmology Times;2/20/95, Vol. 20 Issue 8, p1 

    Reports on a new drug for cytomegalovirus retinitis called Vistide (cidofovir). Route of administration; Side effects; Advantages of the treatment.

  • Retinitis drug available under treatment IND.  // Drug Topics;9/18/95, Vol. 139 Issue 18, p8 

    Reports on the availability of vistide or cidofovir intravenous under a treatment investigational new drug program for eligible patients with relapsing cytomegalovirus retinitis.

  • Studies compelling on alternative IV drug. Murray, Louann // Ophthalmology Times;10/30/95, Vol. 20 Issue 42, p8 

    Reports on the efficacy of intravenous cidofovir in treating relapsing cytomegalovirus retinitis. Report presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; Contact information.

  • ORAL CMV TREATMENT EFFECTIVE.  // AIDS Patient Care & STDs;Jun2002, Vol. 16 Issue 6, p305 

    Examines the efficacy of valganciclovir in treating cytomegalovirus retinitis in patient with AIDS. Conversion of the oral drug to ganciclovir in the body following intake; Demonstration of disease progression on patients treated with the drug; Achievement of a satisfactory treatment response...

  • Two-drug treatment is effective against recurrent CMV retinitis.  // AIDS Patient Care & STDs;Apr96, Vol. 10 Issue 2, p131 

    Reports on the effectiveness of the combination of the drugs foscarnet and ganciclovir in the treatment of cytomegalovirus (CMV retinitis. Precautions in the use of the two-drug therapy.

  • Combination therapy effective.  // Ophthalmology Times;4/1/96, Vol. 21 Issue 13, p5 

    Reports on the National Eye Institute study which indicate that recurring cytomegalovirus (CM) retinitiscan be controlled twice as long if two drugs are taken instead of just one. Factors to consider before making treatment decisions; Negatives about the two-drug regimen; Side effects; Other...

  • CMV retinitis therapy updated. Mandava, Suresh // Ophthalmology Times;07/15/96, Vol. 21 Issue 20, p11 

    Presents advances in the treatment of cytomegalovirus (CMV) retinitis at the 1996 conference of the Association for Research in Vision and Ophthalmology. Treatment; Risks and complications.

  • SPONTANEOUS HEALING OF A CYTOMEGALOVIRUS ESOPHAGEAL ULCERATION IN A PATIENT WITH ACQUIRED IMMUNODEFICIENCY SYNDROME. Wilcox, C. Mel; Schwartz, David A. // American Journal of Gastroenterology;Dec1993, Vol. 88 Issue 12, p2111 

    Presents a case study involving a patient with Candida esophagitis and cytomegalovirus esophageal ulceration who had spontaneous healing of the esophageal ulcer without institution of antiviral or immune modulating agents. Drugs administered to the subject; Remission of infections and neoplasms...

  • CYTOMEGALOVIRUS: A NEW GASTROINTESTINAL PATHOGEN IN IMMUNOCOMPROMISED PATIENTS. Dieterich, Douglas T. // American Journal of Gastroenterology;Aug1987, Vol. 82 Issue 8, p764 

    Provides information on the cytomegalovirus (CMV), a herpes virus with double standard DNA common among transplant recipients and patients with AIDS. Ways in which the cytomegalovirus may be transmitted; Body organs commonly affected by the virus; Information on a nontoxic drug found to be...

  • Treatment of Cytomegalovirus Esophagitis in Patients With Acquired Immune Deficiency Syndrome: A Randomized Controlled Study of Foscarnet Versus Ganciclovir. Parente, F.; Porro, G. Bianchi // American Journal of Gastroenterology;Mar1998, Vol. 93 Issue 3, p317 

    Objective: Although several uncontrolled studies have shown that the response rate to ganciclovir and foscarnet for all forms of cytomegalovirus (CMV) infection in immunocompromised patients is almost similar, to date, no controlled clinical trial has been specifically designed to compare these...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics